On Tuesday, June 4, the next meeting of the Transparency Council.
AOTMiT: Transparency Council on lymphoma and hypertension, among others
Published May 27, 2024 09:35
Źródło: AOTMiT
The agenda includes:
1 Prepare a position paper on the evaluation of the drug Yescarta (axicabtagene ciloleucel) under the drug program B.12.FM. "Treatment of patients with B-cell lymphoma (ICD-10: C82, C83, C85)" ASCT line.
2 Prepare a position paper on the evaluation of the drug Yescarta (axicabtagene ciloleucel) under the drug program B.12.FM. "Treatment of patients with B-cell lymphoma (ICD-10: C82, C83, C85)" non-ASCT line.
3 Prepare a position paper on the evaluation of the drug Adcetris (brentuximabum vedotinum) within the framework of the drug program "Treatment of patients with classical hodgkin's lymphoma (ICD-10: C81)".
4 Prepare an opinion on the continuation of coverage of medicines containing the active substance carvedilolum in the indication: congestive heart failure in cases other than those specified in the ChPL - in children under 18 years of age.
5 Prepare an opinion on the continuation of coverage of medicines containing the active substance benazeprilum in the indication: renoprotective treatment in children under 18 years of age.
6. Prepare an opinion on the continuation of the inclusion in reimbursement of drugs containing the active substance spironolactonum in the indication: arterial hypertension other than those specified in the ChPL - in children under 18 years of age.
7. Prepare an opinion on the continuation of the inclusion in reimbursement of medicines containing the active substance candesartanum cilexetilum in the indications: arterial hypertension in children under 6 years of age; chronic kidney disease in children under 18 years of age; renoprotective treatment in children under 18 years of age.
8. preparation of an opinion on the continuation of the inclusion in reimbursement of medicines containing the active substance ramiprilum in the following indications: chronic kidney disease other than those specified in the SmPC - in children under 18 years of age; renoprotective treatment in cases other than those specified in the SmPC - in children under 18 years of age.
9. Prepare an opinion on the continuation of the inclusion in reimbursement of medicines containing the active substance enalaprilum in the following indications: heart failure other than that specified in the ChPL - in children under 18 years of age; chronic kidney disease in children under 18 years of age; renoprotective treatment in children under 18 years of age.
10. Prepare an opinion on the continuation of the inclusion in reimbursement of medicines containing the active substance quinaprilum in the following indications: arterial hypertension other than those specified in the ChPL - in children from 6 to 18 years of age; chronic kidney disease in children from 6 to 18 years of age; renoprotective treatment in children from 6 to 18 years of age.
11. Prepare an opinion on the continuation of the inclusion in reimbursement of medicines containing the active substance losartanum in the following indications: arterial hypertension other than specified in the SmPC - in children under 18 years of age; chronic kidney disease other than specified in the SmPC - in children under 18 years of age; renoprotective treatment in cases other than specified in the SmPC - in children under 18 years of age.
12. Prepare an opinion on the continuation of the inclusion in reimbursement of medicines containing the active substance telmisartanum in the following indications: arterial hypertension other than those specified in the ChPL - in children under 18 years of age; chronic kidney disease in children under 18 years of age; renoprotective treatment in children under 18 years of age.
13. Prepare an opinion on the continuation of the inclusion in reimbursement of medicines containing the active substance valsartanum in the following indications: arterial hypertension other than those specified in the ChPL - in children under 6 years of age; chronic kidney disease in children under 18 years of age; renoprotective treatment in children under 18 years of age.
Source: AOTMiT
